Product Description: PFK-015, a derivative of 3PO, is a specific PFKFB3 inhibitor. PFK-015 inhibits recombinant PFKFB3 with an IC50 value of 110 nM and inhibits PFKFB3 activity in cancer cells with an IC50 value of 20 nM. PFK-015 can be used for the research of multiple cancers such as lung cancer, stomach cancer, colon cancer and esophageal squamous cell carcinoma (ESCC)[1][2].
Applications: Cancer-programmed cell death
Formula: C17H12N2O
References: [1]Jia Bo Zheng, et al. Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer. Oncoimmunology. 2022 May 25;11(1):2079182. /[2]Brian Clem, et al. Characterization of a novel small molecule antagonist of 6-phosphofructo-2-kinase that suppresses glucose metabolism and tumor growth. ORAL PRESENTATIONS - PROFFERED ABSTRACTS/ APRIL 15 2011.
CAS Number: 4382-63-2
Molecular Weight: 260.29
Compound Purity: 99.80
Research Area: Cancer; Metabolic Disease; Inflammation/Immunology
Solubility: DMSO : 25.2 mg/mL (ultrasonic;warming)
Target: Autophagy
Deutsch
English
